Ucb S.a. · EURONEXT:UCB
Ucb — H1 2022 Earnings Presentation
30 slides from Ucb's earnings presentation, Jul 28, 2022
Slide 1: Half-Year 2022: Strong first six months
Half-Year 2022 Strong first six months - underlying strong resilience and continued delivery Capital Market Earnings Call 28 July 2022
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will”, “continue” and similar expressions. These forward-looking stat
Slide 3: Agenda
Jean-Christophe Tellier Strong first six months - underlying strong Opening CEO resilience and continued delivery Iris Loew-Friedrich CLINICAL PIPELINE Next Wave of Regulatory Submissions Starting Q3 CMO DELIVERING Six Phase 3 Assets Proprietary and Confidential Property of UCB Charl van Zyl Executi
Slide 4: Strong first six months - underlying strong resilience and continued delivery
Strong first six months - underlying strong resilience Proprietary and Confidential Property of UCB and continued delivery Jean-Christophe Tellier CEO 4
Slide 5: 2022 HY Performance | At-a-glance
2022 HY Performance | At-a-glance Strong first six months – strong resilience and continued delivery Revenue € 2.93 billion Net Sales € 2.70 billion (+5%; +3% CER) (+2%; 0% CER) Underlying Profitability (adj. EBITDA) € 814 million or 28% of revenue (-3%; -2% CER) Proprietary and Confidential Propert
Slide 6: ESG Ratings – Positive Interim 2022 Update
ESG Ratings – Positive Interim 2022 Update • Leading business ethics framework AA • Updated code of conduct • Increased reporting and transparency on access to medicines Proprietary and Confidential Property of UCB ESG Rating distribution 6
Slide 7: Upcoming News Flow Confirmed
Upcoming News Flow Confirmed Q3 2022 onwards By the end of 2022 End of 2022 23 February 2023 2023 Submission for market Submission of Bimekizumab in Full-Year Results 2022 Submission for market authorization response to the Hidradenitis authorization for Complete Response Suppurativa (HS) – MT1621 i
Slide 8: Clinical Pipeline Delivering Next Wave of Regulatory Submissions
Clinical Pipeline Delivering Next Wave of Regulatory Proprietary and Confidential Property of UCB Submissions Starting Q3 Six Phase 3 Assets Iris Loew-Friedrich CMO 8
Slide 9: Execution in Focus: Bringing our Phase Successes to Patients
Execution in Focus: Bringing our Phase 3 Successes to Patients 2021 & 2022 Q3 2022 onwards Six positive Phase 3 read-outs Next wave of global regulatory submissions • bimekizumab • zilucoplan in gMG • bimekizumab in AS & nr-axSpA (U.S., EU, GB, JPN, RoW) (EU, GB, JPN, RoW) • rozanolixizumab Propriet
Slide 10: UCB Late-Stage Pipeline | Wave of Submissions & New Phase 3 Assets
UCB Late-Stage Pipeline | Wave of Submissions & 2 New Phase 3 Assets PHASE 1 PHASE 2 PHASE 3 FILING BIMZELX® (bimekizumab; IL-17A&F inhibitor) Available to patients in EU/EEA, GB, JPN, Psoriasis CAN; Resubmission to US-FDA end of 2022* Psoriatic arthritis Starting submissions in Q3 2022 Axial spondy
Slide 11: The Comprehensive Approach to Generalized Myasthenia Gravis
The Comprehensive Approach to Generalized Myasthenia Gravis Two new therapeutic mechanisms Zilucoplan SC self-injection (Phase 3 RAISE study) Rozanolixizumab SC infusion (Phase 3 MycarinG study) Myasthenia Gravis Activities of Daily Living at Week 12 Myasthenia Gravis Activities of Daily Living at D
Slide 12: MT1621 in Thymidine Kinase Deficiency Disorder
MT1621 in Thymidine Kinase 2 Deficiency Disorder An ultra-rare debilitating and life-threatening (often fatal) genetic mitochondrial disorder Prevalence: Thymidine kinase 2 deficiency (TK2d) There are an estimated ~2,100 TK2d patients in the targeted geographies* Is an ultra-rare, inherited, debilit
Slide 13: With FINTEPLA, UCB Offers New Hope
With FINTEPLA®, UCB Offers New Hope… …for patients and families living with challenging developmental and epileptic encephalopathies Dravet Syndrome Lennox-Gastaut Syndrome CDKL5 Deficiency Disorder (DS) (LGS) (CDD) ~12k-15k ~60k-100k ~8k-10k US, EU, JPN prevalence US, EU, JPN prevalence US, EU, JPN
Slide 14: Strong Position in Neurology
Strong Position in Neurology Leading in Epilepsy – Launching Proprietary and Confidential Property of UCB FINTEPLA® Launch Excellence in gMG Charl van Zyl Executive Vice President Neurology Solutions & Head of EU and International Markets 14
Slide 15: Continued Strong Performance from Leading Epilepsy Portfolio
Continued Strong Performance from Leading Epilepsy Portfolio Impacts from loss of exclusivity to VIMPAT®/U.S. and E KEPPRA®/Japan – new addition FINTEPLA® 2022 HY Net sales € 2 705 million1 million ACT CER (+2%; 0% CER) In the U.S., strong performance in the beginning BIMZELX® Proprietary and Confid
Slide 16: Neurology Solutions Strategy
Neurology Solutions Strategy Key driver of mid & long-term growth Continue to lead Successful launch into Partnering for impact in in epilepsy myasthenia gravis Parkinson’s/Alzheimer’s Proprietary and Confidential Property of UCB Increasing focus on more Poised to be leading player Global partnershi
Slide 17: Leading in Epilepsy: Focus on FINTEPLA
Leading in Epilepsy: Focus on FINTEPLA® Opportunity to bringing new hope to many more patients around the world Typically occur in infancy / early childhood, Dravet Syndrome Lennox-Gastaut Syndrome CDKL5 Deficiency Disorder high-risk of sudden unexpected death in (DS) (LGS) (CDD) epilepsy (SUDEP), f
Slide 18: Leading in Myasthenia Gravis: Unique and Complementary Assets
Leading in Myasthenia Gravis: Unique and Complementary Assets Launch readiness maximizing UCB medical expertise and patient insights Establishing Enabling Optimising Highlighting differentiated sustainable patient true need portfolio access experience Proprietary and Confidential Property of UCB Ke
Slide 19: Expanding Portfolio in Immunology
Expanding Portfolio in Immunology Proprietary and Confidential Property of UCB Strong Performance with CIMZIA® and EVENITY®, and Strong Launch Momentum with BIMZELX® Emmanuel Caeymaex Executive Vice President Immunology Solutions & Head of U.S. 19
Slide 20: Commercial Execution in Immunology
Commercial Execution in Immunology Strong product growth and strong launches 2022 HY Net sales Immunology € 2 705 million1 (+2%; 0% CER) € 1 013 million (+16%; +8% CER) BIMZELX® EVENITY® Proprietary and Confidential Property of UCB million ACT CER Outperforms anti-TNF market based on differentiation
Slide 21: Strong BIMZELX uptake across global launch markets
Strong BIMZELX® uptake across global launch markets Reaching over 1,600 patients worldwide in June 2022 Europe (DE, UK, NL & SE) Canada Japan Accelerating growth post-lockdowns trends with IL-23 uptakes strong start vs IL17s Cumulative monthly doses from Cumulative monthly patients Cumulative monthl
Slide 22: Increasing Dynamic Shares in IL-17 Psoriasis Market Segment
Increasing Dynamic Shares in IL-17 Psoriasis Market Segment Across Launch Markets Reaching more and more patients – fueling growth in market shares… Proprietary and Confidential Property of UCB >1.5% >4% >15% >20% Launch + 6 weeks Launch + 11 weeks Launch + 37 weeks Launch + 43 weeks Dynamic Share:
Slide 23: Solid Financial Foundation - protecting profitability
2022 HY Performance Solid Financial Foundation - protecting profitability in the Proprietary and Confidential Property of UCB near- and longer-term Sandrine Dufour CFO 23
Slide 24: 2022 HY Financial Highlights
2022 HY Financial Highlights HY 2022 Actual CER Net Sales € 2 705 million +2% (-1% CER) € 2 925 Revenue Driven by good portfolio growth, compensated by generic erosion to Vimpat/U.S. and +5% +3% million E Keppra/Japan; Other revenue with one-off € 70m Gross margin declined from 75% to 71% due to FIN
Slide 25: Updated Financial Guidance for 2022 - Confirmed
Updated Financial Guidance for 2022 - Confirmed As of 24 June 2022 Revenue expected € 5.30 - 5.40bn Peak sales guidance Proprietary and Confidential Property of UCB Continued core products growth, loss of exclusivity for E KEPPRA® in Japan, for VIMPAT® in the U.S. and the EU, FINTEPLA® sales Adjuste
Slide 26: Active Management of Financial Situation Ongoing
Active Management of Financial Situation Ongoing Protecting profitability in • Focused resource allocation the near- and longer-term • Disciplined cost approach Proprietary and Confidential Property of UCB • Dynamic portfolio management Includes management of erosion curves, delay of bimekizumab • V
Slide 27: Guidance 2025
Guidance 2025 At least € 6bn top line Financial guidance Low- to mid-thirties adj. EBITDA margin Improved ESG rating performance Proprietary and Confidential Property of UCB 2025 How We Get There… Topline Evolution Building Blocks Margin BRIVIACT® 2025 NAYZILAM® Adjusted EVENITY® Gross Improving tha
Slide 28: Conclusion
CEO Conclusion Jean-Christophe Tellier 28 Proprietary and Confidential Property of UCB
Slide 29: UCB showed strong first six months and continued delivery
UCB showed strong first six months underlying strong resilience and continued delivery Confident in our future and our ability to deliver Proprietary and Confidential Property of UCB … managing …to bring BIMZELX® … deliver 2025 to people living with objectives • erosion curves psoriasis in the U.S.
Slide 30: Thank you… your questions, please
Proprietary and Confidential Property of UCB Thank you… your questions, please Proprietary and Confidential Property of UCB 30